Venture Breakfast Bits, by 24/7 Market News

Venture Market News for January 3, 2019

  • Kraig Biocraft Laboratories Completes Final Facilities Review for First Batch of Recombinant Spider Silk Production in Vietnam

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk-based fibers, announces today that key members of its management and production team have laid the groundwork for the Company’s Vietnamese spider silk production initiative.

Full press release

  • The Green Organic Dutchman Signs a Commercial Sublicense with EnWave and Tilray to Dry Cannabis in Canada

TORONTO, Jan. 3, 2019 /PRNewswire/ – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX : TGOD) (US : TGODF) is pleased to announce it has signed a royalty-bearing commercial sublicense (the “Agreement”) with EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”) and Tilray, Inc. (NASDAQ:TLRY) (“Tilray”).

Full press release

  • CV Sciences, Inc. Named One of the First U.S. Hemp Authority™ Certified Manufacturers

LAS VEGAS, Jan. 03, 2019 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “we” or “our”), a preeminent supplier and manufacturer of hemp CBD products through its industry-dominating brand PlusCBD Oil™, is proud to announce its certification by the US Hemp Authority™ Guidance Program.

Full press release

  • Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements for Excellagen® Wound Healing Collagen Matrix

Generex Biotechnology Corporation (OTCMKTS:GNBT) today announced that its partially, soon to be fully-owned subsidiary, Olaregen Therapeutix, Inc. has signed critical manufacturing agreements for Excellagen® with Collagen Solutions, a highly-regarded supplier of medical grade collagen biomaterials for use in research, medical devices, and regenerative medicine applications, and with Berkshire Sterile Manufacturing (BSM), a state-of-the art, GMP fill/finish manufacturer providing formulation and sterile filling as well as analytical development and stability services to the biotech and pharmaceutical industries. The two contract manufacturers will produce and package Excellagen in two dose formulations for the initial product launch in the first quarter of 2019, with a third dosage option for large wounds to follow shortly thereafter.

Full press release

  • Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic

NORTHVALE, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of an antibiotic product. This is the third ANDA that Elite co-developed and filed with SunGen Pharma, LLC (“SunGen”).  According to QVIA (formerly QuintilesIMS Health) data the branded product for this antibiotic and its equivalents had total annual U.S. sales of approximately $94 million for the twelve months ending September 30, 2018.

Full press release

  • NaturalShrimp, Inc. Receives U.S. Patent for System it Developed to Grow Gourmet-Grade Shrimp in Enclosed, Salt-Water System

DALLAS, TX, Jan. 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NaturalShrimp, Inc. (OTCQB: SHMP) is pleased to announce that NaturalShrimp and F&T Water Solutions, LLC have received U.S. Patent No. 10,163,199 B2 for the Recirculating Aquaculture System and Treatment Method for Aquatic Species developed for the first commercially viable system for growing aquatic species indoors.  NaturalShrimp maintains the exclusive worldwide rights for any and all shrimp species utilizing this patent dated December 25, 2018.

Full press release

Connect with 24/7 Market News on social media

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.


24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. 24/7MN owns KBLB shares that it can sell at any time. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice.   24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to 

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements


24/7 Market News

[email protected]

Add New Playlist